A Study of the Long-Term Safety, Tolerability, and Effectiveness of Tesevatinib for Patients Completing 24 Months of Treatment for Autosomal Dominant Polycystic Kidney Disease

Overview

Información sobre este estudio

The purpose of this study is to assess the long term safety, tolerability, and effectiveness of tesevatinib for patients with autosomal dominant polycystic kidney disease, who started and completed 24 months of treatment for previous study KD019-101.

 

 

 

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria

  • Must have received 24 months of treatment with tesevatinib on study KD019-101 (includes days without treatment that were allowed by the KD019-101 protocol)
  • If sexually active, has agreed to use two forms of an accepted method of contraception during the course of the study and for 3 months after the last dose of study drug
    • Effective birth control includes 
      • IUD plus one barrier method
      • Stable doses of hormonal contraception for at least 3 months (eg, oral, injectable, implant, transdermal) plus one barrier method
      • 2 barrier methods
    • Effective barrier methods are
      • Male or female condoms
      • Diaphragms
      • Spermicides (creams or gels that contain a chemical to kill sperm)
  • Females of childbearing potential must have a negative pregnancy test at screening
    • Females of childbearing potential are defined as
      • Sexually mature women without prior hysterectomy 
      • Have had any evidence of menses in the past 12 months
      • Have been amenorrheic for 12 or more months, if the amenorrhea is possibly due to prior chemotherapy, anti-estrogens, or ovarian suppression

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Ziad El-Zoghby, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20263278

Mayo Clinic Footer